Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jan 25:2021:6635618.
doi: 10.1155/2021/6635618. eCollection 2021.

Characterizing Advanced Parkinson's Disease: Romanian Subanalysis from the OBSERVE-PD Study

Affiliations

Characterizing Advanced Parkinson's Disease: Romanian Subanalysis from the OBSERVE-PD Study

Jozsef Attila Szasz et al. Parkinsons Dis. .

Abstract

OBSERVE-PD was a cross-sectional, multicountry, observational study conducted in 128 Movement Disorders Centers (MDCs) in 18 countries. Overall, the study enrolled 2615 patients. The aim was to determine the proportion of patients with advanced Parkinson's disease (APD) versus non-APD from MDCs and to uncover the clinical burden of APD, as well as a correlation between overall assessment of APD and several indicators of APD. The advanced stage of the disease and severity were assessed by investigators using their clinical judgement. Data were collected during a single visit between February 2015 and January 2016. Agreement on physician judgement of APD diagnosis and fulfillment of at least one previously established APD indicator was calculated. Motor and nonmotor symptoms (NMSs), activities of daily living, treatment complications, quality of life (QoL), conventional treatments, and device-aided therapy (DAT) eligibility were assessed. Here, country-specific results of 161 Romanian patients with PD are presented. In total, 59.0% of patients were diagnosed with APD and 78.8% met at least one APD indicator. There was only moderate agreement between clinical judgement of APD and overall fulfillment of APD indicators. All scores related to motor symptoms, NMSs, and treatment complications, as well as to QoL, showed a higher disease burden for patients with APD versus non-APD. Physicians considered 73.7% of patients with APD eligible for DAT. The majority of patients eligible for DAT (54.3%) did not receive such treatment. Our results highlight the importance of earlier recognition of APD, by combining clinical judgement with more standardized clinical tools, such as generally recognized APD criteria. However, timely diagnosis of APD alone is not enough to improve patient outcomes. Other critical factors include patient acceptance and access to appropriate treatment.

PubMed Disclaimer

Conflict of interest statement

J. A. Szasz was a study investigator and declares speaker fees from AbbVie, Novartis, UCB, Boehringer-Ingelheim, GSK, Ever, Lundbeck, Teva, and Pfizer; D. C. Jianu was a study investigator; M. A. Simu was a study investigator and received fees from Teva, AbbVie, Merck, Servier Pharma, AOP Orphan, Boehringer-Ingelheim, Sanofi, Krka, and UCB Pharma; V. A. Constantin was a study investigator and reports fees from AbbVie, UCB, and Wörwag Pharma; A. O. Dulamea was a study investigator and reports speaker fees from AbbVie, Teva, Merck, Sanofi-Genzyme, Pfizer, AstraZeneca, Boehringer-Ingelheim, Novartis, UCB Pharma, and Roche; K. Onuk is an employee of AbbVie; D. Popescu is an employee of AbbVie; M.-T. Vasile was a study investigator and received fees from Teva, AbbVie, Lundbeck, and Boehringer-Ingelheim; and B. O. Popescu was a study investigator. A. Fasano was a study investigator and has served as an advisor for AbbVie Inc. and consultant for Abbott, Medtronic, Boston Scientific, Ipsen, Sunovion, and AbbVie Inc. He has received research support from Abbvie, Medtronic, Boston Scientific, University of Toronto, Michael J. Fox Foundation for Parkinson's Research, and honoraria from Abbott, Brainlab, UCB Pharma, Medtronic, Novartis, Chiesi, Boston Scientific, AbbVie Inc., Ipsen, Sunovion, and Teva for serving as a speaker. O. A. Bajenaru received speaker and consulting fees from AbbVie SLR and speaker fees from Lundbeck, UCB Pharma, and Boehringer-Ingelheim.

References

    1. Poewe W., Mahlknecht P. The clinical progression of Parkinson’s disease. Parkinsonism & Related Disorders. 2009;15(4):S28–S32. doi: 10.1016/s1353-8020(09)70831-4. - DOI - PubMed
    1. Hoehn M. M., Yahr M. D. Parkinsonism: onset, progression, and mortality. Neurology. 1967;50(2):318–334. - PubMed
    1. de Lau L. M., Breteler M. Epidemiology of Parkinson’s disease. The Lancet Neurology. 2006;5(6):525–535. doi: 10.1016/s1474-4422(06)70471-9. - DOI - PubMed
    1. GBD 2016 Parkinson’s Disease Collaborators. Global, regional, and national burden of Parkinson’s disease, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurology. 2018;17(11):939–953. - PMC - PubMed
    1. Dauer W., Przedborski S. Parkinson’s disease. Neuron. 2003;39(6):889–909. doi: 10.1016/s0896-6273(03)00568-3. - DOI - PubMed

LinkOut - more resources